Thrombosis News and Research RSS Feed - Thrombosis News and Research

Thrombosis is the formation or presence of a thrombus (blood clot) inside a blood vessel.
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
MD Anderson researchers find significant clinical variations among liver cancer patients

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center. [More]
Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need. [More]
Lung cancer surgery patients at higher risk of developing venous thromboembolism

Lung cancer surgery patients at higher risk of developing venous thromboembolism

New evidence suggests that lung cancer surgery patients are at higher risk of developing venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), than previously thought, with elevated risks of complications or death. When thromboemboli occur, they may be asymptomatic or attributed to post-surgical pain or complications, and may reflect both the lung cancer itself as well as compromised lung function after surgery. [More]
Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death. [More]
Boehringer Ingelheim seeks FDA approval for Pradaxa to treat DVT and PE

Boehringer Ingelheim seeks FDA approval for Pradaxa to treat DVT and PE

Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Pradaxa's maker, Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for its blood thinner to treat DVT and PE. [More]
HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare Ventricular Assist System meets primary endpoint in ENDURANCE clinical trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint. [More]
New Forsyth Institute study sheds light on connection between the mouth and heart

New Forsyth Institute study sheds light on connection between the mouth and heart

A new study from the Forsyth Institute is helping to shed more light on the important connection between the mouth and heart. According to research recently published online by the American Heart Association, scientists at Forsyth and Boston University have demonstrated that using an oral topical remedy to reduce inflammation associated with periodontitis, more commonly known as gum disease, also results in the prevention of vascular inflammation and can lower the risk of heart attack. [More]
New article highlights need for optimization of warfarin therapy

New article highlights need for optimization of warfarin therapy

Warfarin can be a challenging drug to manage. Long-term anticoagulation is recommended for patients with atrial fibrillation at risk of stroke, and for those with recurrent venous thrombosis or prosthetic heart valves. [More]
UM experts warn of serious risks associated with common IV devices

UM experts warn of serious risks associated with common IV devices

Every day, patients around the country get IV devices placed in their arms, to make it easier to receive medicines or have blood drawn over the course of days or weeks. But these PICC lines, as they're called, also raise the risk of potentially dangerous blood clots. [More]
Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO). [More]
Janssen announces acquisition of XO1

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. [More]
Extended dual antiplatelet therapy after DES implantation increases mortality

Extended dual antiplatelet therapy after DES implantation increases mortality

Data from a meta-analysis published today in The Lancet found that extended duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT. [More]
Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. [More]
'Turbocharged' protein holds promise in hemophilia gene therapy

'Turbocharged' protein holds promise in hemophilia gene therapy

Using gene therapy to produce a mutant human protein with unusually high blood-clotting power, scientists have successfully treated dogs with the bleeding disorder hemophilia, without triggering an unwanted immune response. [More]
Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera. [More]
Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

New evidence published today in the Cochrane Library shows that hormone replacement therapy does not protect post-menopausal women against cardiovascular disease, and may even cause an increased risk of stroke. [More]
New ASH report outlines several models for 'systems-based clinical hematologist'

New ASH report outlines several models for 'systems-based clinical hematologist'

A report released today from the American Society of Hematology in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today’s rapidly changing U.S. health-care system. [More]
SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France. [More]
Majority of ACS NSQIP hospitals improve surgical outcomes over time

Majority of ACS NSQIP hospitals improve surgical outcomes over time

The majority of hospitals participating in the American College of Surgeons National Surgical Quality Improvement Project improve surgical outcomes over time, and improvement continues with each year that hospitals participate in the program, according to a new study published online today in Annals of Surgery. [More]
Advertisement
Advertisement